Form 4 for NAGE Niagen Bioscience, Inc.
Accepted 2024-12-13 00:00:00 ET · period of report 2024-12-13 · accession 0001628280-24-051264 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-12-13 | 2024-12-13 | NAGE | Jaksch Frank L Jr | Dir | M - OptEx | $3.66 | +50.0K | 281.3K | +22% | +$183.0K |
| D | 2024-12-13 | 2024-12-13 | NAGE | Jaksch Frank L Jr | Dir | S - Sale+OE | $6.19 | -37.2K | 244.2K | -13% | -$230.0K |
| D | 2024-12-13 | 2024-12-13 | NAGE | Jaksch Frank L Jr | Dir | M - OptEx | $0.00 | -50.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-13 | M | A | 50,001 | $3.66 | 281,340 | D | — | — | |
| 2 | Common | Common Stock | 2024-12-13 | S | D | 37,161 | $6.19 | 244,179 | D | — | — | (F2) The weighted average sale price for the transaction reported was $6.1881, and the range of prices were between $6.13 and $6.285. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. (F1) The sale of shares was solely to cover the exercise cost and associated taxes for the exercise of the options which were scheduled to expire on July 5, 2025. As a result of the exercise of the options, the Reporting Person will own 12,840 more shares. |
| 3 | Derivative | Employee Stock Options (right to buy) | 2024-12-13 | M | D | 50,001 | $0.00 | 0 | D | $3.66 · 2016-07-06 to 2025-07-05 | 50,001 Common Stock |